Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperationspartner / Sponsor Evaluation der digitalen Gesundheitsanwendung consilium care™ bei Patienten mit HER2-positivem Brustkrebs während einer Chemotherapie in Kombination mit einer HER2-zielgerichteten Antikörper-Therapie: Eine multizentrische, randomisierte, kontrollierte Studie Onkologie Dr. med. Baumann Christa palleos healthcare GmbH, Campus SLB Methods for localization of different types of breast lesions Onkologie PD Dr. med. Berclaz Gilles EUBREAST, Campus SLB, Lindenhofgruppe und weitere Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial. (OPBC-01/SAKK 23/16 / IBCSG 57-18 / ABCSG-53 / GBG-101) Onkologie PD Dr. med. Berclaz Gilles Universitätsspital Basel, Campus SLB, Lindenhofgruppe Prostate Cancer Outcomes – Compare & Reduce Variation in DKG-zertifizierten Prostatakrebszentren Onkologie PD Dr. med. Böhlen Dominik DKG, Insel Gruppe, Campus SLB, Lindenhofgruppe und weitere A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 24-02 BIG 2-02 SOFT) Onkologie Prof. Dr. med. Borner Markus IBCSG, Campus SLB, Lindenhofgruppe und weitere A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (IBCSG 25-02 BIG 3-02 TEXT) Onkologie Prof. Dr. med. Borner Markus IBCSG, Campus SLB, Lindenhofgruppe und weitere Helping Ourselves, Helping Others: The Young Women’s Breast Cancer Study (IBCSG 43-09 HoHo) Onkologie Prof. Dr. med. Borner Markus IBCSG, Campus SLB, Lindenhofgruppe und weitere Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer (RESCUE) Onkologie Prof. Dr. med. Borner Markus NOGGO, Campus SLB, Lindenhofgruppe und weitere Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 – A Non-Inferiority Phase III Trial (SAKK 96/12 REDUSE) Onkologie Prof. Dr. med. Borner Markus SAKK, Campus SLB, Lindenhofgruppe und weitere Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: the ERYT/CoordiFit randomized controlled trial Onkologie Prof. Dr. med. Borner Markus Universität Bern, Campus SLB, Lindenhofgruppe und weitere A multicenter, observational cohort study of women undergoing Immediate breast Reconstruction following MAstectomy (IRMA) Onkologie Dr. med. Brühlmann Yves Brustzentrum Thurgau, Campus SLB, Lindenhofgruppe und weitere 81 Geschäftsbericht 2022 Lindenhofgruppe Lehre und Forschung
RkJQdWJsaXNoZXIy MzQxOTE=